Overexpression of the structural maintenance of chromosome 4 protein is associated with tumor de-differentiation, advanced stage and vascular invasion of primary liver cancer

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1263-1268

  Zhou, Bo ^a   Yuan, Tao ^a   Liu, Menggang ^a   Liu, Hongming ^a   Xie, Jun ^a   Shen, Yanbin ^a   Chen, Ping ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Hepatocellular carcinoma; Primary liver cancer; Structural maintenance of chromosome 4

Indexed keywords

CHROMOSOME PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA; STRUCTURAL MAINTENANCE OF CHROMOSOME PROTEIN 4; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FEMALE; FLOW CYTOMETRY; GENE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURAL MAINTENANCE OF CHROMOSOME 4 GENE; TUMOR DEDIFFERENTIATION; TUMOR DIFFERENTIATION; TUMOR VOLUME; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATASES; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; REFERENCE VALUES;

EID: 84866459404     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1929     Document Type: Article

References (34)

1. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.
2. Ozenne V, Bouattour M, Goutté N, et al: Prospective evaluation of the management of hepatocellular carcinoma in the elderly. Dig Liver Dis 43: 1001-1005, 2011.
3. Lau WY and Lai EC: Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 7: 237-257, 2008.
4. Hawkins MA and Dawson LA: Radiation therapy for hepatocellular carcinoma from palliation to cure. Clin Cancer Res 106: 1653-1661, 2006.
5. Takayama T: Surgical treatment for hepatocellular carcinoma. Jpn J Clin Oncol 41: 447-454, 2011.
6. Cha CH, Saif MW, Yamane BH and Weber SM: Hepatocellular carcinoma: current management. Curr Probl Surg 47: 10-67, 2010.
7. Ma S, Jiao B, Liu X, et al: Approach to radiation therapy in hepatocellular carcinoma. Cancer Treat Rev 36: 157-163, 2010.
8. Wertheim JA, Petrowsky H and Saab S: Major challenges limiting liver transplantation in the United States. Am J Transplant 11: 1773-1784, 2011.
9. Wiggermann P, Jung EM and Stroszczynski C: Radiofrequency ablation is a technique finished? Radiologe 52: 9-14, 2012.
10. Liapi E and Geschwind JF: Medium-sized HCC: achieving effective local tumor control with combined chemoebolization and radiofrequency ablation. Ann Surg Oncol 18: 1527-1528, 2011.
11. Smerdou C, Menne S, Hernandez-Alcoceba R and Gonzalez-Aseguinolaza G: Gene therapy for HCV/HBV-induced hepatocellular carcinoma. Curr Opin Investig Drugs 11: 1368-1377, 2010.
12. Truty MJ and Vauthey JN: Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique. Ann Surg Oncol 17: 1219-1225, 2010.
13. Abelev GI, Perova SD, Khramkova NI, Postnikova ZA and Irlin IS: Production of embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation 1: 174-180, 1963.
14. Lok AS, Sterling RK, Everhart JE, et al: Des-ã-carboxy prothrombin and á-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138: 493-502, 2010.
15. Giardina MG, Matarazzo M, Varriale A, Morante R, Napoli A and Martino R: Serum alpha-L-fucosidase: a useful marker in the diagnosis of hepatocellular carcinoma. Cancer 70: 1044-1048, 1992.
16. Ishizuka H, Nakayama T, Matsuoka S, et al: Prediction of the development of hepato-cellular carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity. Intern Med 38: 927-931, 1999.
17. Zhu ZW, Friess H, Wang L, et al: Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 48: 558-564, 2001.
18. Allegretta M and Filmus J: Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma. Anticancer Agents Med Chem 11: 543-548, 2011.
19. Oka H, Tamori A, Kuroki T, Kobayashi K and Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 19: 61-66, 1994.
20. Ishii M, Gama H, Chida N, et al: Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. Am J Gastroenterol 95: 1036-1040, 2000.
21. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ and Lok AS: Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 37: 1114-1121, 2003.
22. Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME and Min AD: Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol 95: 1535-1538, 2000.
23. Trevisani F, D'Intino PE, Morselli-Labate AM, et al: Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34: 570-575, 2001.
24. Toyoda H, Kumada T, Kiriyama S, et al: Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 4: 111-117, 2006.
25. Nakamura S, Nouso K, Sakaguchi K, et al: Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 101: 2038-2043, 2006.
26. Uto H, Kanmura S, Takami Y and Tsubouchi H: Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers. Proteome Sci 8: 70, 2010.
27. Sherman M: Alphafetoprotein: an obituary. J Hepatol 34: 603-605, 2001.
28. Losada A and Hirano T: Dynamic molecular linkers of the genome: the first decade of SMC proteins. Genes Dev 19: 1269-1287, 2005.
29. Lu KH, Patterson AP and Wang L: Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10: 3291-3300, 2004.
30. Kulawiec M, Safina A, Desouki MM, Still I, Matsui S, Bakin A and Singh KK|: Tumorigenic transformation of human breast epithelial cells induced by mitochondrial DNA depletion. Cancer Biol Ther 7: 1732-1743, 2008.
31. Li J, Zhang N, Song LB, et al: Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res 14: 3319-3326, 2008.
32. Freeman L, Aragon-Alcaide L and Strunnikov A: The condensin complex governs chromosome condensation and mitotic transmission of rDNA. J Cell Biol1 49: 811-824, 2000.
33. Yu L, Peña Castillo L, Mnaimneh S, Hughes TR and Brown GW: A survey of essential gene function in the yeast cell division cycle. Mol Biol Cell1 7: 4736-4747, 2006.
34. Wang Y, Klijn JG, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679, 2005.